Avadel Pharmaceuticals plc (AVDL)’s Stock Is Buy After Today’s Big Increase

December 7, 2017 - By Marguerite Chambers

The stock of Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a huge mover today! The stock increased 7.64% or $0.63 during the last trading session, reaching $8.88. About 343,033 shares traded or 24.31% up from the average. Avadel Pharmaceuticals plc (NASDAQ:AVDL) has risen 3.59% since December 7, 2016 and is uptrending. It has underperformed by 13.11% the S&P500.
The move comes after 9 months positive chart setup for the $353.09 million company. It was reported on Dec, 7 by Barchart.com. We have $9.24 PT which if reached, will make NASDAQ:AVDL worth $14.12M more.

Analysts await Avadel Pharmaceuticals plc (NASDAQ:AVDL) to report earnings on March, 6. After $0.09 actual earnings per share reported by Avadel Pharmaceuticals plc for the previous quarter, Wall Street now forecasts -355.56 % negative EPS growth.

Avadel Pharmaceuticals PLC identifies, develops, and commercializes pharmaceutical products for primary care and sterile injectable markets in the United States, France, and Ireland. The company has market cap of $353.09 million. The companyÂ’s owns and develops drug delivery platforms, such as Micropump, a microparticulate system that allows the development of modified and/or controlled release of solid and oral dosage formulations of drugs; LiquiTime, which allows development of modified/controlled release liquid suspension formulations; Trigger Lock that allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse; and Medusa, a hydrogel depot technology that allows the development of extended/modified release of injectable dosage formulations of drugs. It has a 4.58 P/E ratio. The Company’s lead products include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection used to treat hypotension; and Akovaz, an ephedrine sulfate injection.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.